Navigation Links
Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
Date:11/24/2008

esearcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited three books, and written four others, including the best-selling textbook, Essential Psychopharmacology, now in its third edition and the best-selling clinical manual, Essential Psychopharmacology Prescriber's Guide.

Dr. Sheehan has been a consultant to the World Health Organization, the World Federation of Societies of Biological Psychiatry, the International Academy for Biomedical and Drug Research, the US Food and Drug Administration, and a research grant reviewer for the National Institute for Mental Health (NIMH). Dr. Sheehan has been invited to give over 1600 lectures in 64 countries throughout the world on anxiety and mood disorders, psychopharmacology and biological psychiatry. He was elected as a member of the American College of Psychiatrists and is a Distinguished Fellow of the American Psychiatric Association.

    About Labopharm's Novel Trazodone Formulation and the Market for
    Antidepressants

One-half of patients being treated with antidepressants discontinue therapy within a year for reasons related to efficacy and/or tolerability, including delayed onset of therapeutic response, insomnia or sleep disturbance, agitation, exacerbation of anxiety, sexual dysfunction, weight gain and somnolence. Labopharm has developed a novel once-daily formulation of 150 mg and 300 mg of trazodone hydrochloride, a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rat
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... in PLOS Pathogens , children who live in ... mount an immune response to infection with malaria parasites ... high fever and illness and partially control the growth ... help researchers develop future interventions that prevent or mitigate ... year, approximately 200 million cases of malaria occur worldwide, ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... Annapolis Media ... Event, ANNAPOLIS, Md., Sept. ... will have used,an inhalant by the 8th grade. In Maryland, inhalant use is ... are,the drug of choice, with use rates over twice the rate of marijuana ...
... 28 With audience members cheering and,famous Chicago chefs ... cooker for the finalists at Consorta,s Battle of the ... as the organic cucumbers he,serves the patients at Saint ... the event,s Gold Chef Award, becoming the reigning champion ...
... "Tonight the candidates,lost an opportunity to engage in ... dominate people,s day to day lives. (Logo: ... in the African American,community, with one in four adults ... able to afford to retire. "With just one ...
... has recently inspired research into its therapeutic value ... prevention. A painful, progressive autoimmune disease, rheumatoid ... of depressiondouble the risk of the healthy population, ... Increasingly, RA patients are turning to alternative ...
... raised in bilingual homes learned two similar-sounding words in a ... raised in homes where only one language is spoken. This ... appears to be due to the fact that bilingual babies ... words and objects (often a word in each language) for ...
... In a victory for the,families of small business ... legislation that will improve accessibility of the State,Children,s ... and Olympia Snowe (R-Maine) attached an amendment to ... to enroll more,children in the program. The provision ...
Cached Medicine News:Health News:National Battle of the Hospital Chefs Cooks Up a Winner 2Health News:Post-Debate Statement from AARP Board Member Joyce Payne 2Health News:Meditation therapy for rheumatoid arthritis patients 2Health News:Meditation therapy for rheumatoid arthritis patients 3Health News:Babies raised in bilingual homes learn new words differently than infants learning one language 2Health News:Babies raised in bilingual homes learn new words differently than infants learning one language 3Health News:Bipartisan Bill Expands Health Care Access for Small Businesses 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... January 11, 2012 Simbionix USA Corporation, ... training, is pleased to announce that advanced virtual reality ... in addition to English. The new languages ... system, MentorLearn™. MentorLearn is available either as the new ...
... 11, 2012  Suneva Medical, a privately-held aesthetic medical device ... study to investigate the efficacy of Artefill for the ... being conducted at 10 centers throughout the U.S. and ... "Acne can have lasting effects on a patient,s ...
Cached Medicine Technology:Simbionix Comprehensive Medical Simulators now Available in Additional Languages 2Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study 2
Standard knife with box, C profile...
... The Cryostage freezing stage is a refrigerated ... object holder, primarily for use with the 8000 ... other sledge microtomes. ,The refrigerated stage gives a ... the surface is ridged to provide good adhesion ...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
... MNL 4404 & 4405 series Freezing Stages fit ... have no moving parts and need only the ... for operation. Freezing starts immediately and ... adjustable so that optimum cutting temperatures can be ...
Medicine Products: